| Literature DB >> 35935339 |
Min Yang1, Peijia Lin1, Wei Jing1, Haokun Guo1, Hongnian Chen1, Yuanyuan Chen1, Yi Guo1, Yixue Gu1, Miaoqing He1, Junhong Wu1, Xuejun Jiang2,3, Zhen Zou4,3, Xin Xu1, Chengzhi Chen3,5, Fei Xiao1, Xuefeng Wang1, Xin Tian1.
Abstract
Epilepsy is a common disease of the nervous system. Autophagy is a degradation process involved in epilepsy, and in turn, seizures can activate autophagy. Beclin1 plays a critical role in autophagy and participates in numerous physiological and pathological processes. However, the mechanism underlying the effect of Beclin1 on epilepsy remains unclear. In this study, we detected increased expression of Beclin1 in brain tissues from patients with temporal lobe epilepsy (TLE). Heterozygous disruption of beclin1 decreased susceptibility to epilepsy and suppressed seizure activity in two mouse epilepsy models. We further illustrated for the first time that heterozygous disruption of beclin1 suppresses excitatory synaptic transmission, which may be caused by a decreased dendritic spine density. These findings suggest for the first time that the regulation of Beclin1 may serve as a strategy for antiepileptic therapy. In addition, Beclin1 participates in synaptic transmission, and the development of dendritic spines may be a biological function of Beclin1 independent of its role in autophagy.Entities:
Keywords: Beclin1; dendritic spines; epilepsy; excitatory synaptic transmission; transgenic mice
Year: 2022 PMID: 35935339 PMCID: PMC9354790 DOI: 10.3389/fnmol.2022.807671
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 6.261
Clinical characteristics of patients with intractable TLE and control patients.
| Number | Sex (M/F) | Age (Years) | Course (Years) | AEDs taken before surgery |
| T1 | F | 26 | 7 | CBZ, VPA, OXC, TPM |
| T2 | M | 22 | 5 | CBZ, TPM, CZP |
| T3 | F | 25 | 10 | CBZ, PB, LTG, LEV |
| T4 | M | 24 | 8 | VPA, CBZ, TPM, PB |
| T5 | M | 18 | 7 | PHT, PB, CBZ, VPA |
| T6 | F | 35 | 10 | CBZ, VPA, TPM, OCX |
| T7 | F | 22 | 9 | CBZ, TPM, CZP |
| T8 | M | 29 | 14 | CBZ, LTG, LEV, PB |
| C1 | M | 11 | 0 | None |
| C2 | F | 38 | 0 | None |
| C3 | M | 40 | 0 | None |
| C4 | F | 34 | 0 | None |
| C5 | M | 30 | 0 | None |
| C6 | F | 17 | 0 | None |
| C7 | M | 11 | 0 | None |
| C8 | M | 25 | 0 | None |
T, TLE temporal lobe epilepsy; C, control; M, male; F, female; CBZ, carbamazepine; LTG, lamotrigine; LEV, levetiracetam; OXC, oxcarbazepine; PHT, phenytoin; PB, phenobarbital; TPM, topiramate; VPA, valproic acid.
FIGURE 1Beclin1 expression was increased in patients with TLE and epileptic mice. (A,B) Beclin1 protein levels in patients with traumatic brain injury (TBI) and patients with epilepsy (n = 8 patients per group). (C,D) The Beclin1 protein levels in cortex and hippocampus from wild-type (WT) mice and kainic acid (KA)-treated mice (n = 8 mice per group). (E,F) The Beclin1 protein levels in cortex and hippocampus from WT mice and pentylenetetrazol (PTZ)-treated mice (n = 8 mice per group). (G,H) IF staining and semi-quantitative analysis of Beclin1 puncta fluorescence intensity in cortical and hippocampal tissues from patients with temporal lobe epilepsy (TLE) and two epileptic mouse models (n = 50 samples per group). Scale bars: 50 μm. Data are presented as the means ± SEM, **p < 0.01. Student’s t-tests were performed.
FIGURE 2Autophagy was activated in epilepsy but suppressed in beclin1± mice. (A,B) LC3-II/LC3-I protein levels in the cortex and hippocampus of brain tissues from wild-type (WT) and epilepsy model mice (n = 3 mice per group). (C,D) p62 protein levels in the cortex and hippocampus of brain tissues from WT and epilepsy model mice (n = 3 mice per group). (E,G) LC3-II/LC3-I and p62 protein level in cultured primary neurons from WT and beclin1± mice under basal conditions and upon autophagy induction (RAPA)/blockade (3-MA) (n = 3 samples per group). (H) Nissl staining of WT and beclin1± mouse brain slices. Scale bars: 52 μm. (I) The viability of cultured neurons dissected from WT and beclin1± mice was detected using the MTT assay (n = 6 samples per group). Data are presented as the means ± SEM. *p < 0.05 and **p < 0.01. Student’s t-tests and one-way ANOVA were performed.
FIGURE 3Knockdown of beclin1 decreased seizure susceptibility and epileptic activity. (A,B) Quantitative analysis of the spontaneous recurrent seizure (SRS) latency and total number of SRSs in the kainic acid (KA)-induced epilepsy model in the two groups (n = 10 mice per group). (C,D) Mean seizure scores recorded after the injection of pentylenetetrazol (PTZ) in the two groups on alternate days (n = 10 mice per group). (E) Representative traces of local field potentials (LFPs) from the wild-type (WT) and beclin1± groups. (F–H) Quantitative analysis of the number, time spent, and duration of seizure-like event (SLE) of the LFPs from two groups (n = 8 mice per group). Data are presented as the means ± SEM. *p < 0.05 and **p < 0.01. Group differences in the mean seizure score during PTZ kindling were evaluated with repeated-measures ANOVA. Student’s t-tests were performed.
FIGURE 4Knockdown of beclin1 affected excitatory synaptic transmission. (A) Representative traces of mEPSCs and miniature inhibitory postsynaptic currents (mIPSCs) from the two groups. (B,C) Quantitative analysis of the frequency and amplitude of the mEPSCs [wild-type (WT) group: n = 10, beclin1± group: n = 8]. (D,E) Quantitative analysis of the frequency and amplitude of the mIPSCs (n = 12 per group). (F) Representative traces of NMDAR-mediated and AMPAR-mediated EPSCs from the two groups. (G–I) Summary of the EPSC amplitude from the two groups (n = 6 per group). (J) Representative traces of the paired-pulse ratios (PPRs) for AMPA-mediated EPSCs at three different interstimulus intervals. (K) Summary of the PPRs between the two groups (n = 6 per group). Data are presented as the means ± SEM. *p < 0.05 and **p < 0.01. Student’s t-tests were performed.
FIGURE 5Beclin1 was colocalized with an excitatory synaptic protein. (A) Representative image showing the distributions of Beclin1 and the excitatory postsynaptic protein PSD-95 in mouse brain sections. (B) The extent of the colocalization was quantified using Image-Pro Plus software. (C) Representative image showing the distributions of Beclin1 and the excitatory presynaptic protein vGluT1 in mouse brain sections. (D) The extent of colocalization was quantified [wild-type (WT) group: n = 11, beclin1± group: n = 9]. Data are presented as the means ± SEM. Scale bars: 50 μm. Student’s t-tests were performed.
FIGURE 6Knockdown of beclin1 altered the dendritic spine density. (A) Representative image of the apical dendritic spine morphology of pyramidal neurons in brain slices from wild-type (WT) and beclin1± mice detected using Golgi staining. Scale bars: 5 μm. (B,C) Quantification of the apical and basal dendritic spine density in the two groups (n = 5 mice/genotype, 21 cells from WT mice and 16 cells from beclin1±). (D,E) Representative image of dendrites and PSD-95/vGluT1 staining in cultured neurons from the two groups. (F) Quantification of the dendritic spine density and PSD-95/vGluT1 puncta density in the two groups (n = 12 cells). (G,H) Representative image and quantification of the dendritic spine density in cultured neurons from WT and beclin1± mice under basal conditions and upon autophagy induction (RAPA) (n = 3 mice/genotype, 15 neurons per group). Spines on apical dendrites in the stratum radiatum (SR) located within 20 μm from the soma were counted. Data are presented as the means ± SEM. *p < 0.05 and **p < 0.01. Student’s t-tests and one-way ANOVA were performed.